Fco de Paula Titos

🦀 Radiation Oncologist ⚛️ H.U.Badajoz / SBRT & SRS/ @oncoradioHUVM "Mors mortem superavit"

[Joaquín J Cabrera. PhD. @JoaquinJCabrera]

We present our results with the single fraction in NSCLC and lung metastases. We highlight the excellent results and convenience in an aging population with comorbidities and geographically dispersed. #ESTRO26 #SABR

[Oncología Radioterápica HUVM @oncoradioHUVM]

‼️Seguimos de congreso‼️
Compartimos nuestra partipación con diferentes ponencias y comunicaciones orales
Radioterapia de vanguardia ☢️
@HUVMacarena @AndaluzaSac

[Oncología Radioterápica HUVR @oncoradioHUVR]

Sentido homenaje a la Dra. Elena Montero en el Congreso de la Sociedad Andaluza de Cancerología. Alegría, vocación y legado imborrable. Siempre en nuestros corazones.

[Oncología Radioterápica HUVM @oncoradioHUVM]

Amplia representación de nuestro servicio en el XXIV Congreso Andaluz de Cancerología: la sociedad oncológica más antigua de España @AndaluzaSac
#radonc ☢️

[Joaquín J Cabrera. PhD. @JoaquinJCabrera]

😎
Innovación, precisión y equidad: así aborda Badajoz el cáncer de pulmón. #lcsm https://t.co/ZVohX1kKKF

[Oncología Radioterápica HUVM @oncoradioHUVM]

‼️Os compartimos un resumen de las recientes guias de contorneo de la SBRT renal ‼️

[Cardiología La Paz @CardioHULP]

Hoy hemos recibido las peores de las noticias

Nuestro querido compañero Jesús Saldaña ha fallecido en la catástrofe de Adamuz

Todos lo recordamos con mucho amor. Era una persona excepcional y única que daba todo para los pacientes y todos sus compañeros. Que descanse en paz.

[Evan Thomas MD/PhD @EvanThomas84]

Shout out to the SAMURAI protocol for looking at what we should’ve been doing 20 years ago.

Treating the primary w/ SABR in metastatic RCC is such a no-brainer. No downtime and no seeding like CARMENA.

Many of these tumors have vascular involvement and are obvious seeders.

This is a young KPS 100 gentleman with newly diagnosed RCC with a few brain mets, a few small lung mets, and a 9cm primary.

He got postop fSRS to brain met cavity with treatment of two intact lesions w/in 2 wks surgery.

He’ll get 4500/5fx SABR (w/ GTV SIB to 5500) to the primary completed w/in 3 wks.

All this completed before insurance has even finished authing his initial dose of keytruda/lenvima.

Small lung nodules will be systemic therapy index, and can be SBRT’d to NED if they don’t respond.

[LARVOL @Larvol]

Top #LungCancer Oncologists for November 2025, curated by @LARVOL CLIN.

Explore more about oncology conferences, top trials, and reactions from oncologists: https://t.co/ct6tMIQHii

#LARVOL #Oncology #CancerResearch #CancerData #OncologyInsights #ClinicalTrials #LCSM | @StephenVLiu | @M_Torasawa | @JoaquinJCabrera | @gerryhanna | @LeXiuning | @BalazsHalmosMD | @RManochakian | @diegoadiazg | @NormandBlais | @ADesaiMD

[SEOR.es @SEOR_ESP]

🎯Objetivo del nuevo presidente de la Sociedad Española de Oncología Radioterápica (SEOR), @drjavierserrano: mayor visibilidad a la especialidad en varios ámbitos.
#radioterapia #oncologiaradioterapica

https://t.co/hgbVsTItiT

[Joaquín J Cabrera. PhD. @JoaquinJCabrera]

La radioterapia no es solo máquinas ⚙️ y dosis 📏: es salvar vidas o mejorarlas 💖. Si la enseñamos bien, los estudiantes lo entienden y se enamoran 😍. ¡Cambiemos la percepción! 🔥 #radonc
. Para muestra un botón:

[Peter Mac Cancer Centre @PeterMacCC]

We’re thrilled to welcome delegates from across the world for the Peter Mac SABR Symposium 2025.

Led by Prof @_ShankarSiva, it brings together global leaders in stereotactic ablative body radiotherapy for two days of cutting-edge learning, interactive sessions and expert panels

[Shankar Siva @_ShankarSiva]

Extraordinary case at #SABR2025 by @drspdavid and De Mark Shaw @PeterMacRadOnc oligoprogressive #breastcancer without switching drug therapy. 8 years of SABR with #radonc, with preserved quality of life from the patient’s perspective!!! #bcsm

[Shankar Siva @_ShankarSiva]

@BarbaraJereczek gives an overview of SABR in #prostatecancer…. Hard to beat, when one of her patients could RUN A MARATHON between one of his 5 sessions of curative treatment!!! #pcsm

[Shankar Siva @_ShankarSiva]

@PBlanchardMD discusses SABR in oligometastatic #prostatecancer #pcsm - in both hormone sensitive and castrate resistant patients… and reminds us that lung metastases have a similar prognosis to bone secondaries; and the HR of benefit is the same in all studies ~0.50 #SABR2025

[Shankar Siva @_ShankarSiva]

😲@Melissa_O_Neil tells us the nuts and bolts of sim-free #radiotherapy at #SABR2025 - from pre-plan adaptive, one stop RT, and ‘on the fly SABR’ on the table … 😳
➡️ making #radonc faster, more accessible and attractive for our patients!

[prof. Barbara Jereczek-Fossa @BarbaraJereczek]

#SABR2025 and ARREST trial, “The number is not the limit”🚀

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Most expert GU oncologists were supportive of discussing de-escalation of systemic ADT+ARPI in mHSPC #ProstateCancer after achieving PSA<0.2 ng/ml at 2024 @APCCC_Lugano conference 👉 Dr @Silke_Gillessen discusses mHSPC de-intensification trials @13th EOC👇@OncoAlert @PCF_Science

[Uğur Özkerim @UOzkerim]

🚀 LUNAR Trial
In oligorecurrent HSPC, adding 2 cycles of ¹⁷⁷Lu-PSMA before SBRT more than doubles PFS (7.4 → 17.6 months) — a 63% reduction in progression, without added toxicity.

🔬 98% of progressions were new PSMA PET lesions, underscoring the power of targeting micrometastatic disease early.

📌 Importantly, it also delays the need for ADT— a major quality-of-life win.

📈 A compelling signal heading toward Phase III validation
@OncoAlert @MedwatchKate @weoncologists @OncoReporte @TresUramigas @Uromigos

[Pierre Blanchard, MD @PBlanchardMD]

Tour de force talk by Melissa O Neil on polymetastatic SBRT at #SABR2025.
Lessons learned from ARREST trials. Key principles of therapy. Is it the next #radonc frontier? Integration with biology and systemic therapy will be key as well.